Tanezumab: Additional Phase II data

The double-blind, U.S. Phase II RN624-CL006 trial in 450 patients with moderate-to-severe knee pain due to OA of the knee showed that 10, 25, 50, 100 and 200 µg/kg doses of tanezumab significantly reduced knee pain from baseline by 45-62% vs. 22% for placebo at week 16 (p<0.001 for all). Tanezumab also significantly increased mean PGA scores by 29-47% vs. 19% for placebo (p<0.001 for all). Additionally, the rate of response according to OMERACT-OARSI criteria was significantly higher for all doses of tanezumab vs. placebo (74-93% vs. 44%, p<0.001 for all). Data were published in The New England Journal of Medicine. ...